Antitrust claims that have already cost GlaxoSmithKline $175 million to settle are potentially even more expensive now that a federal judge in Philadelphia has green-lighted a second suit that alleges nearly identical claims, reported Shannon Duffy in today’s Legal Intelligencer article, Sham Shame? Drug Co. Faces Another Antitrust Action Based on Allegedly Bogus Patent Suit. ChemiSpA v. GlaxoSmithKline